Yinhuang granule alleviates carbon tetrachloride-induced liver fibrosis in mice and its mechanism

BACKGROUND Liver fibrosis is a formidable global medical challenge,with no effective clinical treatment currently available.Yinhuang granule(YHG)is a proprietary Chinese medicine comprising Scutellariae Radix and Lonicerae Japonicae Flos.It is frequently used for upper respiratory tract infections,pharyngitis,as well as acute and chronic tonsillitis.AIM To investigate the potential of YHG in alleviating carbon tetrachloride(CCl4)-induced liver fibrosis in mice.METHODS To induce a hepatic fibrosis model in mice,this study involved intraperitoneal injections of 2 mL/kg of CCl4 twice a week for 4 wk.Meanwhile,liver fibrosis mice in the low dose of YHG(0.4 g/kg)and high dose of YHG(0.8 g/kg)groups were orally administered YHG once a day for 4 wk.Serum alanine/aspartate aminotransferase(ALT/AST)activity and liver hydroxyproline content were detected.Sirius red and Masson's trichrome staining assay were conducted.Realtime polymerase chain reaction,western-blot and enzyme-linked immunosorbent assay were conducted.Liver glutathione content,superoxide dismutase activity level,reactive oxygen species and protein carbonylation amount were detected.RESULTS The administration of YHG ameliorated hepatocellular injury in CCl4-treated mice,as reflected by decreased serum ALT/AST activity and improved liver histological evaluation.YHG also attenuated liver fibrosis,evident through reduced liver hydroxyproline content,improvements in Sirius red and Masson's trichrome staining,and lowered serum hyaluronic acid levels.Furthermore,YHG hindered the activation of hepatic stellate cells(HSCs)and ameliorated oxidative stress injury and inflammation in liver from CCl4-treated mice.YHG prompted the nuclear accumulation of nuclear factor erythroid 2-related factor 2(Nrf2)and upregulated the expression of Nrf2-dependent downstream antioxidant genes.In addition,YHG promoted mitochondrial biogenesis in liver from CCl4-treated mice,as demonstrated by increased liver adenosine triphosphate content,mitochondrial DNA levels,and the expression of peroxisome proliferator-activated receptor gamma coactivator 1 alpha and nuclear respiratory factor 1.CONCLUSION YHG effectively attenuates CCl4-induced liver fibrosis in mice by inhibiting the activation of HSCs,reducing inflammation,alleviating liver oxidative stress damage through Nrf2 activation,and promoting liver mitochondrial biogenesis.

Clinical Effect of Yinhuang Qingfei Capsules in Treatment of Asymptomatic and Mild/Common Severe Acute Respiratory Syndrome Coronavirus 2 Infection:An Analysis of 242 Cases

[Objectives]To investigate the clinical effect of Yinhuang Qingfei capsules in the treatment of asymptomatic and mild/common severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.[Methods]A total of 362 patients with SARS-CoV-2 infection were divided into the treatment group with 242 patients and control group with 120 patients according to their treatment regimen.The patients in the control group were given standard treatment regimen and those in the treatment group were given Yinhuang Qingfei capsules in addition to the treatment in the control group.The two groups were observed in terms of average length of hospital stay,mean time for nucleic acid clearance,TCM syndrome score,and progression to severe/critical illness,and clinical outcome was compared between the two groups.[Results]There was a significant difference in the overall response rate between the treatment group and the control group[97.52%(236/242)vs 95.00%(114/120),P<0.05].Compared with the control group,the treatment group had significantly shorter length of hospital stay and time for nucleic acid clearance(P<0.05).After 7 days of treatment,both groups had a significant change in TCM syndrome score,and there was a significant difference in TCM syndrome score between the two groups(P<0.05);after 15 days of treatment,both groups had a TCM syndrome score of 0.Progression to severe/critical illness was not observed in either group.[Conclusions]Compared with the standard treatment regimen alone,standard treatment regimen combined with Yinhuang Qingfei capsules can effectively shorten the length of hospital stay and time for nucleic acid clearance and improve TCM symptoms in patients with asymptomatic and mild/common SARS-CoV-2 infection.

Rapid analysis of spatial distribution of PVPP and hardness of Yinhuang dispersible tablets by NIR-CI

The present study aimed at investigating the relationship between tablet hardness and homogeneity of different Yinhuang dispersible tablets by near-infrared chemical imaging(NIR-CI)technology.The regularity of best hardness was founded between tablet hardness and the spatial distribution uniformity of Yinhuang dispersible tablets.The ingredients homogeneity of Yinhuang dispersible tablets could be spatially determined using basic analysis of correlation between analysis(BACRA)method and binary image.Then different hardnesses of Yinhuang dispersible tablets were measured.Finally,the regularity between tablet hardness and the spatial distribution uniformity of Yinhuang dispersible tablets was illuminated by quantifying the agglomerate of polyvinyl poly pyrrolidone(PVPP).The result demonstrated that the distribution of PVPP was unstable when the hardness was too large or too small,while the agglomerate of PVPP was smaller and more stable when the best tablet hardness was 75 N.This paper provided a novel methodology for selecting the best hardness in the tabletting process of Chinese Medicine Tablet.

Evaluation Study on Urine Metabolomics in Yinhuang(阴黄)Rat Model Induced by Triplet Factors of Rhubarb,Ethanol,andα-Nephthylisothiolyanate

Objective： To ascertain the biomarkers capable to characterize the animal composite model of Chinese medicine （CM） Yinhuang （阴黄） syndrome induced by triplet factors of rhubarb, ethanol, and a-nephthylisothiolyanate （abbreviated as R, E, and A below） through metabolomic study and to evaluate the established model by means of studying the sources of markers based on the changes of metabolites produced from various combinations of the three modeling drugs. Methods： Eighty Wistar rats allocated equally in eight groups （A-H） were treated with saline, R＋E＋A, R, E, A, R＋E, R＋A, and E＋A, respectively. Rats＇ 12 h urine in the 14 successive experimental days were collected separately using metabolic cages and analyzed by ultra peformance liquid chromatograph/time of flight mass spectrometer （UPLC/TOF-MS） to create the metabolic contour graph of urine in different groups for identifying the differences between them. The similarities and differences of metabolic network among various groups were represented from microcosmic viewpoint by pattern recognition method （principal component analysis）. Results： Controlled by group A, the landing points in principal component map of various groups were apparently assorted, especially obvious on the 14th day; 19 biomarkers, which capable to represent the genesis and development process of the Yinhuang syndrome in the triplet factors-induced rat model, were identified. Conclusion： Metabolomic method is successfully used in evaluating the animal model of CM syndrome. Furthermore, according to the holistic view and substance changes in vivo, the influences of disease on organism were comprehensively analyzed, and the pathogenic mechanism of CM Yinhuang syndrome was explored at the level of metabolomics in rive as well.

茵黄益肠合剂对脾胃虚弱型糖尿病性腹泻患者血糖、血脂及炎性标志物的影响

目的 观察茵黄益肠合剂对脾胃虚弱型糖尿病性腹泻患者血糖、血脂及炎性标志物的影响。方法 选取2022年8月—2023年7月昆明市中医医院收治的脾胃虚弱型糖尿病性腹泻患者60例,按入院时间先后顺序随机分为观察组和对照组各30例。对照组采用西医常规治疗,观察组在对照组的基础上加用茵黄益肠合剂治疗,2组疗程均为14 d。比较2组治疗前后血糖指标[空腹血糖(FPG)、果糖胺(FA)]、血脂指标[总胆固醇(TC)、三酰甘油(TG)]、炎性标志物[C反应蛋白(CRP)、白介素-6(IL-6)、降钙素原(PCT)、血清淀粉样蛋白(SAA)]及不良反应。结果 治疗14 d后,2组血清FPG、FA、TC、TG、CRP、IL-6、PCT及SAA水平较治疗前降低,且观察组血清FPG、TC、TG、CRP、IL-6、PCT水平低于对照组(P<0.05或P<0.01),而2组FA、SAA水平比较差异无统计学意义(P>0.05)。2组整个服药过程中均未发现明显不良反应。结论 茵黄益肠合剂治疗脾胃虚弱型糖尿病性腹泻的效果优于单纯西医治疗,能显著改善血糖、血脂及炎性标志物水平,且未发现明显不良反应,安全性较高。

播期对宁夏引黄灌区不同品种青贮玉米光能利用及生物产量的影响

为探究播期对宁夏引黄灌区麦收后复种不同品种青贮玉米光能利用和生物产量的影响,采用裂区试验设计,选择早熟‘科沃028’(Z)和中晚熟‘利合629’(W)2个青贮玉米品种为主区,设置麦收后3(S1,6月28日)、6(S2,7月1日)、9 d(S3,7月4日)3个播期为副区,共计6个处理,研究不同播期对不同品种青贮玉米光能利用、干物质积累及生物产量的影响,并拟合推测不同品种青贮玉米的最适播期及收获期。结果表明:Z较W处理整体上有更高的叶面积指数(LAI)、光能利用率(LUE)、光合生产潜力开发度(r)、干物质积累量(DM)和生物产量(BY)。Z处理整个生育时期LAI大小顺序均为ZS1>ZS2>ZS3。在生育后期(麦收后95 d),ZS3处理的植株底部透光率(BLT)和LUE较ZS1和ZS2处理分别显著提高13.81%、5.40%和15.02%、23.49%(P<0.05);麦收后107 d,ZS1和ZS2处理的BY与麦收后100 d相比分别显著下降22.47%和17.37%(P<0.05)。各处理在其最适收获期收获,产量大小顺序为ZS1>ZS2>ZS3>WS2>WS1>WS3。相关性分析结果表明2个品种LUE均与其BY呈极显著正相关关系(P<0.001),而与r呈极显著负相关关系(P<0.001)。主成分分析发现ZS2处理综合评价最优。综上所述,建议宁夏引黄灌区早熟品种生长85 d后(麦收后6~8 d播种)收获,而中晚熟品种生长86 d后(麦收后5~6 d播种)收获。

银黄含片对H1N1流感小鼠炎症因子表达的影响研究

目的评价银黄含片对H1N1流感小鼠的药效,观察其对H1N1流感小鼠炎症因子表达水平的影响。方法采用流感病毒H1N1CA07滴鼻建立H1N1小鼠模型,奥司他韦组与银黄含片组分别予奥司他韦及银黄含片溶液灌胃7 d。观察小鼠肺指数及病毒指数。采用高通量液相蛋白芯片检测小鼠血清IFN-γ、IL-12p70、IL-17A、IP-10、MIP-1β、ENA-78。结果银黄含片组肺指数较模型组显著降低,模型组小鼠IL-12p70、ENA-78和IL-17A水明显降低(P<0.01),IP-10明显增高(P<0.01)。银黄含片组IFN-γ水平与MIP-1β水平较奥司他韦组均明显降低P<0.05)。结论银黄含片能够明显减少H1N1小鼠的肺损伤,并明显降低IFN-γ与MIP-1β水平,推测银黄含片很可能是通过减少T细胞的趋化,降低流感小鼠的Th1免疫应答,从而起到达到肺保护作用。

基于网络药理学探讨茵黄解毒汤治疗HBV相关肝衰竭的活性成分及其作用机制

目的:采用网络药理学方法研究茵黄解毒汤治疗乙型肝炎病毒(hepatitis B virus,HBV)相关肝衰竭(hepatitis B virus related liver failure,HBV-LF)的活性成分及其分子机制。方法:采用GEO数据库筛选疾病相关差异基因(differentially expressed genes,DEGs),TCMSP数据库筛选中药复方小分子化合物及其作用靶点,Venny 2.1.0进行交集比对,确定交集靶点及其关系。运用Cytoscape构建茵黄解毒汤治疗HBV-LF的调控网络,Bisogenet构建蛋白互作网络(protein-protein interaction network,PPI),CytoNCA进行网络拓扑学分析。利用David数据库进行GO富集分析和KEGG信号通路富集分析。结果:本研究共得到HBV-LF的差异基因2160个,茵黄连解毒汤的药物靶点255个,交集靶点31个,相关小分子化合物66个。小分子化合物包括槲皮素、山柰酚、黄芩素、芦荟大黄素、黄连素等。PPI网络涉及55个关键节点,包括TP53、NTRK1、HSP90AA1、ESR1、CUL3、MCM2、CDK2、HSP90AB1、YWHAZ、NPM1、EGFR等。GO富集分析主要与细胞组分构成或来源、对刺激的反应、免疫过程、正/负调节的生物过程、细胞死亡、细胞增殖等有关。KEGG通路27条,主要涉及PI3K-Akt信号通路、MAPK信号通路、Cell cycle、Hepatitis B、自噬、FoxO信号通路、Ras信号通路、IL-17信号通路、NOD样受体信号通路、HIF-1信号通路、NF-κB信号通路等。结论:茵黄解毒汤拮抗HBVLF具有“多靶点-多通路-多作用”的特性,其作用机制可能与促进肝细胞增殖分化、降低肝细胞凋亡、调节机体免疫、抑制HBV复制等有关。

银黄清肺胶囊治疗慢性支气管炎急性发作痰热壅肺证的临床观察

目的探究银黄清肺胶囊治疗慢性支气管炎(chronicbronchitis,CB)急性发作痰热壅肺证的有效性和安全性。方法将60例患者随机分为治疗组和对照组各30例,对照组予以阿奇霉素片;复方福尔可定口服溶液;盐酸氨溴索口服溶液;布洛芬缓释胶囊治疗。治疗组在对照组的基础上加用银黄清肺胶囊。治疗5 d后,比较2组的临床疗效、中医症状积分、止咳时间、祛痰时间、退热时间、炎症因子和不良反应率。结果治疗组临床总有效率为93.33%,对照组为73.33%,2组的临床疗效比较,差异具有统计学意义(P<0.05);与治疗前比较,2组治疗后的中医症状积分、C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)均显著降低(P<0.05);与对照组比较,治疗组治疗后的中医症状积分、止咳时间、祛痰时间、退热时间、CRP、IL-6、TNF-α均显著低于对照组治疗后(P<0.05);2组的不良反应率相当(P>0.05)。结论银黄清肺胶囊具有良好的治疗CB急性发作痰热壅肺证的有效性和安全性,能够加速缓解临床症状和控制炎症反应,具有临床应用的前景。

鼻内镜手术联合苍耳子散合银黄连蒲汤治疗非侵袭性真菌性鼻-鼻窦炎的效果

目的观察鼻内镜手术联合苍耳子散合银黄连蒲汤治疗非侵袭性真菌性鼻-鼻窦炎(NIFRS)的临床效果。方法将2017年4月至2021年10月收治的40例NIFRS患者作为研究对象,按照随机数字表法将其分为对照组和观察组,每组20例。两组均行鼻内镜手术治疗,观察组术后加苍耳子散合银黄连蒲汤治疗。比较两组的临床疗效、临床症状、客观症状和睡眠质量。结果观察组的治疗总有效率为100.00%,略高于对照组的90.00%,但差异无统计学意义(P>0.05)。术前,两组的视觉模拟量表(VAS)、Lund-Kennedy、Lund-Mackay、匹兹堡睡眠质量表(PSQI)评分比较,差异无统计学意义(P>0.05);术后3个月,两组的VAS、Lund-Kennedy、Lund-Mackay、PSQI评分均显著降低,且观察组显著低于对照组,差异具有统计学意义(P<0.05)。结论鼻内镜手术联合苍耳子散合银黄连蒲汤治疗NIFRS,可在一定程度上提高疗效,更利于改善患者的主客观症状、睡眠质量,值得临床推广应用。

基于网络药理学和分子对接分析虎贯茵黄清肝饮治疗乙型病毒性肝炎的作用机制

目的:应用网络药理学及分子对接技术对虎贯茵黄清肝饮治疗乙型病毒性肝炎的活性成分、靶点和作用通路进行分析。方法:通过多个公共数据库获得虎贯茵黄清肝饮中活性成分的潜在靶点和乙型病毒性肝炎的疾病靶点,获得二者的交集靶点,对交集靶点进行基因本体论(GO)功能富集分析和京都基因与基因组百科全书(KEGG)通路富集分析,并将关键靶点与重要活性成分进行分子对接。结果:通过网络药理学分析获得有效活性成分206个、有效活性成分靶点405个、疾病靶点1431个、有效活性成分-疾病交集靶点120个、关键靶点12个。富集的KEGG通路有磷脂酰肌醇3激酶-蛋白激酶B信号通路、癌症通路、缺氧诱导因子-1信号通路等。分子对接显示,核心成分与关键靶点能有效结合。结论:虎贯茵黄清肝饮可能通过细胞凋亡过程的负调节、对异生刺激的反应、基因表达的正向调控、信号转导等作用机制,达到治疗乙型病毒性肝炎的作用。

UPLC-MS/MS法同时测定人血浆中黄芩苷和绿原酸

建立UPLC-MS/MS法同时测定人血浆中黄芩苷和绿原酸的浓度,研究注射用银黄在健康人体的药代动力学.色谱柱为BEH C18（50 mm×2.1 mm ID,1.7μm）;流动相：A（水,0.1%甲酸）,B（甲醇,0.1%甲酸）,梯度洗脱;流速：0.35 mL·min^-1.电喷雾离子源,多反应监测.黄芩苷：[M＋H]^＋,m/z 447-271;绿原酸：[M-H]^-,m/z 353→191;山柰素：[M＋H]^＋,m/z 287→287.结果表明,黄芩苷和绿原酸血药浓度的线性范围分别为9.6～1 540和7.5～1 200 ng·mL^-1,日内、日间精密度均小于10.2%.志愿者静脉滴注注射用银黄后,黄芩苷和绿原酸的药时曲线分别符合二房室和三房室模型.该法简便、灵敏、特异,适用于血浆中黄芩苷和绿原酸浓度的测定.

HPLC-DAD-Q-TOF-MS/MS法的银黄颗粒主要成分定性与定量研究

目的采用高效液相色谱串联四极杆飞行时间质谱（HPLC-Q-TOF-MS/MS）快速鉴定银黄颗粒化学成分和HPLC-DAD法同时定量测定银黄颗粒中15种成分（獐牙菜苷、马钱苷、新绿原酸、绿原酸、隐绿原酸、咖啡酸、芦丁、异绿原酸B、异绿原酸A、异绿原酸C、野黄芩苷、黄芩苷、汉黄芩苷、黄芩素、汉黄芩素）。方法分析采用月旭Ultimate-XB C18色谱柱（4.6 mm×150 mm,5μm）,流动相为乙腈-0.1%甲酸水,梯度洗脱,体积流量0.8 m L/min,柱温30℃。飞行时间质谱,采用负离子模式扫描。二极管阵列检测器的检测波长为240、276、326 nm。结果 HPLC-Q-TOF-MS/MS法推断鉴定银黄颗粒中的44种成分,HPLC-DAD定量分析银黄颗粒中15种成分在考察的质量浓度范围内,与峰面积之间呈良好的线性关系（r〉0.999 0）;回收率均在97.3%~100.9%范围内,RSD为1.4%~2.8%。结论通过HPLC-Q-TOF-MS/MS法和HPLC-DAD法鉴定银黄颗粒的化学成分优于HPLC法,尤其测定环烯醚萜苷类成分（獐牙菜苷、马钱苷）可为综合评价银黄制剂的质量提供参考。

银黄注射液及口服液中绿原酸和黄芩苷在大鼠体内的药动学比较

目的比较银黄注射液和银黄口服液中绿原酸和黄芩苷在大鼠体内的的药物动力学特征。方法10只♂大鼠随机均分成两组,分别iv银黄注射液和ig银黄口服液,用HPLC同时测定不同时间点血浆中绿原酸和黄芩苷的浓度。结果大鼠iv银黄注射液后,血浆中能够同时检出绿原酸和黄芩苷,其中绿原酸的呈三室开放模型,黄芩苷的药?时曲线变化呈二室开放模型;大鼠ig银黄口服液后,血浆中检不出绿原酸,而黄芩苷的药?时曲线呈多峰现象,其绝对生物利用度为15.2%。结论不同的给药途径,绿原酸和黄芩苷在大鼠体内所表现的药物动力学特征相差很大。

银黄冲剂兔体内生物利用度研究

采用ＨＰＬＣ，以银黄冲剂中主要有效成分黄芩甙为测定指标，以银黄注射液为对比，用家兔为实验对象，测定银黄注射液和银黄冲剂单剂量给药后的血药浓度并据此计算银黄冲剂的生物利用度。结果表明，银黄冲剂的血药峰浓度为０．１９５９μｇ／ｍｌ，达峰时间为１．３９ｈ，生物利用度为６１．１９％。该研究为银黄冲剂的内在质量评价提供了一定的依据。

凉血解毒、清热化湿和凉血解毒、健脾温阳法治疗慢性重型肝炎的临床观察

目的观察凉血解毒、清热化湿法(简称清热化湿法)和凉血解毒、健脾温阳法(简称健脾温阳法)治疗慢性重型肝炎阴阳黄证的初步疗效,为黄疸的中医治疗提供思路。方法采用随机、对照方法,进行中医辨证治疗慢性重型肝炎43例,重点观察比较清热化湿、健脾温阳两法消退黄疸的作用。结果治疗4周后,清热化湿组22例,有效16例(72·7%),无效6例(27·3%);健脾温阳组21例,有效19例(90·5%),无效2例(9·5%);两组疗效比较差异无显著性。TBIL:治疗后两组均下降(P<0·01),且健脾温阳组下降的幅度大于清热化湿组(P<0·05);凝血酶原活动度:健脾温阳组上升幅度优于清热化湿组(P<0·05);ALT:两组均降低(P<0·05),但两组间比较差异无显著性。结论凉血解毒、健脾温阳法治疗慢性重型肝炎阴阳黄证的疗效优于凉血解毒、清热化湿法。

毛细管电泳法测定银黄胶囊及银黄颗粒中黄芩苷和绿原酸的含量

目的建立同时测定银黄胶囊及银黄颗粒中黄芩苷和绿原酸含量的方法。方法采用毛细管电泳法，电泳条件：未涂层弹性融硅石英毛细管柱（55cm×75μm ID，有效长度47cm）；以40mmol／L硼砂溶液（pH9．30）为运行缓冲液；分离电压15kV；重力进样5s（高度15cm）；检测波长310nm。结果以对硝基苯甲酸为内标，黄芩苷、绿原酸的线性范围分别为20．2～101．0μg／mL（r=0．9981），5．15—25．75μg／mL（r=0．9991）。银黄胶囊中黄芩苷、绿原酸的平均回收率分别为105.0％、97．2％，银黄颗粒中黄芩苷、绿原酸的平均回收率分别为101．3％、96．6％。结论该法简便、快速、准确可靠，可用于银黄胶囊及银黄颗粒的质量控制。

HPLC法同时测定银黄制剂中的绿原酸和黄芩苷含量

目的:建立同时测定银黄制剂中绿原酸和黄芩苷的 HPLC 方法。方法:色谱柱为 Waters Symmetry C_(18)(3.9 mm×150mm,5μm)柱,以甲醇-0.4%磷酸水溶液为流动相,梯度洗脱(0→15 min,甲醇15%→55%;15→25 min,甲醇55%;25→28min,甲醇55%→15%)。流速为0.8 mL·min^(-1),检测波长为320 nm,0.02 AUFS。结果:绿原酸的线性范围为6.88～110.08μg·mL^(-1)(r=0.9996),平均回收率为97.4%,RSD 为2.2%(n:5);黄芩苷的线性范围为13.40～214.40μg·mL^(-1)(r=0.9998),平均回收率为96.7%,RSD 为2.0%(n=5)。结论:该方法简单、快速、准确,可为银黄制剂的质量控制提供实验依据。

双波长比值光谱法测定银黄口服液中绿原酸和黄芩苷含量

目的 :应用双波长比值光谱法对银黄口服液中绿原酸和黄芩苷含量测定进行研究。方法 :依据绿原酸和黄芩苷的比值光谱特征 ,选择 2 6 6和 34 2nm作为测定波长。结果 :绿原酸线性范围 2～ 2 0 μg/ml,回收率 98.9,RSD为 1.5 8% ;黄芩苷线性范围2～ 16 μg/ml,回收率 10 0 .4% ,RSD为 1.32 %。 结论 :本法为一种灵敏、准确和简便的分析方法 ,可在其他中药制剂中推广应用。

高效液相色谱法测定不同厂家银黄颗粒中绿原酸的含量

目的建立反相高效液相色谱（RP—HPLC）法测定银黄颗粒制剂中绿原酸含量的方法及测定不同厂家银黄颗粒制剂中绿原酸的含量。方法采用RP—HPLC法检测银黄颗粒制剂中绿原酸的含量，色谱条件：Kromasil C18色谱柱，以乙腈-甲醇-0．4％磷酸水溶液（含0．6％三乙胺，5：15：80）为流动相，流速1ml／min，检测波长327nm，柱温为室温。结果绿原酸在6．23×10^-3～100．50×10^-3mg·ml^-1范围内与峰面积呈良好的线性关系（r=0．9998），平均回收率为98．30％。RSD=2．35％（n=6）。结论所建立的色谱方法可以简便、准确测定银黄颗粒中绿原酸的含量，重现性较好。各厂家生产的银黄颗粒中绿原酸含量差别较大，有必要建立绿原酸的定量控制方法。